Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Inclusion Criteria:

• Has persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamouscarcinoma, or adenocarcinoma of the cervix which has not been treated with systemicchemotherapy and is not amenable to curative treatment (such as with surgery and/orradiation). Prior chemotherapy utilized as a radiosensitizing agent and completed atleast 2 weeks prior to randomization with resolution of all treatment-relatedtoxicities is allowed. AEs due to previous treatments should be resolved to ≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia areeligible.

• Not pregnant or breastfeeding, and at least one of the following conditions applies:a.) Not a woman of childbearing potential (WOCBP), b.) A WOCBP must agree to useeffective contraception during the treatment period and for at least 120 days afterthe last dose of pembrolizumab/placebo and 210 days after the last dose ofchemotherapy/bevacizumab

• Has measurable disease per RECIST 1.1 as assessed by the local siteinvestigator/radiology

• Has provided archival tumor tissue sample or newly obtained core or excisionalbiopsy of a tumor lesion not previously irradiated for prospective determination ofProgrammed Cell Death-Ligand 1 (PD-L1) status prior to randomization

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 14 days prior to randomization

• Has adequate organ function

Exclusion Criteria:

• A WOCBP who has a positive urine pregnancy test within 72 hours prior torandomization

• Has known active central nervous system (CNS) metastases and/or carcinomatousmeningitis. Participants with known brain metastases may participate provided thatthe brain metastases have been previously treated (except with chemotherapy) and areradiographically stable.

• Has a known additional malignancy that is progressing or has required activetreatment within the past 3 years. Note: Participants with basal cell carcinoma ofthe skin, squamous cell carcinoma of the skin, transitional cell carcinoma ofurothelial cancer, or carcinoma in situ (e.g. breast cancer) that have undergonepotentially curative therapy are not excluded.

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form ofimmunosuppressive therapy within 7 days prior to randomization

• Has an active autoimmune disease that has required systemic treatment in past 2years (i.e., with use of disease modifying agents, corticosteroids orimmunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, orphysiologic corticosteroid replacement therapy for adrenal or pituitaryinsufficiency) is not considered a form of systemic treatment and is allowed

• Has a history of (non-infectious) pneumonitis that required steroids or has currentpneumonitis

• Has an active infection requiring systemic therapy

• Has a known history of human immunodeficiency virus (HIV) infection

• Has a known history of Hepatitis B or known active Hepatitis C virus infection

• Has a known history of active tuberculosis (TB; Bacillus tuberculosis)

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent orwith an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137)

• Has received prior systemic chemotherapy for treatment of cervical cancer.

• Has not recovered adequately from toxicity and/or complications from major surgeryprior to randomization

• Has received prior radiotherapy within 2 weeks prior to randomization. Participantsmust have recovered from all radiation-related toxicities, not requirecorticosteroids, and not have had radiation pneumonitis.

• Has received a live vaccine within 30 days prior to randomization

• Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of itsexcipients.

• Has a contraindication or hypersensitivity to any component of cisplatin,carboplatin, paclitaxel, or bevacizumab

• Is currently participating in or has participated in a study of an investigationalagent or has used an investigational device within 4 weeks prior to randomization

• Is pregnant or breastfeeding or expecting to conceive within the projected durationof the study, starting with the screening visit through 120 days following last doseof pembrolizumab/placebo and 210 days following last dose ofchemotherapy/bevacizumab

• Has had an allogeneic tissue/solid organ transplant